Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17


1. Dolger H: Clinical evaluation of vascular damage in diabetes mellitus. JAMA 1947, 134:1289–1291.

2. DCCT Research Group:The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus:The Diabetes Control and Complications Trial. N Engl J Med 1993, 329:978–986.

3. The Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1994, 311:365–372.

4. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986, 2(8519):1300–1304.

5. Binchmann-Hansen O, Dahl-Jorgensen K, Hanssen KR, Sandvik L: The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophthalmol 1988, 106:1242–1246.

6. Reichard P, Nilsson B-Y, Rosenqvist U:The effect of long-term insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329:304–309.

7. Nathan DM:The modern management of insulin-dependent diabetes mellitus. Med Clin NA 1988, 72:1365–1378.

8. Nathan DM, Singer DE, Hurxthal K, Goodson JD:The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984, 310:341–346.

9. DCCT Research Group:The absence of a glycemic threshold for the development of long-term complications. Diabetes 1996, 45:1289–1298.

10. Cryer PE, Fisher JN, Shamoon H: Hypoglycemia. Diabetes Care 1994, 17:734–751.

11. Fanelli C, Epifano L, Rambotti AM, et al.: Meticulous prevention of hypo-glycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993, 42:1683–1689.

12. Saleh TY, Cryer PE:Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997, 20:1231–1236.

13. Zinman B,Tildesley H, Chiasson J-L, et al.: Insulin lispro in CSII. Diabetes 1997, 46:440–443.

14. Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 1993, 328:676–685.

15. Galloway JA, Spradlin CT, Howey DC, Dupre J: Intrasubject differences in pharmacokinetic and pharmacodynamic responses: the immutable problem of present-day treatment? In Diabetes. Edited by Serrano-Rios M, Lefebvre PJ. New York: Elsevier Science; 1985.

16. Molnar GD, Taylor WF, Langworthy AL: Plasma immunoreactive insulin patterns in insulin-treated diabetics. Studies during continuous blood glucose monitoring Mayo Clin Proc 1972, 47:709–719.

17. Nathan DM, Lou P, Avruch J: Intensive conventional and insulin pump therapies in type 1 diabetes. A crossover study. Ann Intern Med 1982, 97:31–36.

18. Reichard P, Pihl M: Mortality and treatment side effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994, 43:313–317.

19. Dunn FL, Nathan DM, Scavini M, Selam J-L: Long-term therapy of IDDM with an implantable insulin pump. Diabetes Care 1997, 20:59–63.

20. DCCT Research Group: Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997, 46:1829–1839.

21. Parving HH, Smidt UM, Friisberg B, et al.: A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with nephropathy. Diabetologia 1981, 20:457–461.

22. Klein BEK, Moss SE, Klein R: Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13:34–40.

23. Lewis EJ:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.

24. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995, 102:647–661.

25. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995, 47:1703–1720.

26. DCCT Research Group. Effect of intensive therapy on residual b cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. Ann Int Med 1998, 128:517–523.

27. UNOS. 1997 Annual Report: U.S. Scientific Registry of Transplant Recipients and The Organ Procurement and Transplantation Network. Bethesda, MD: Department of Health and Human Services, ISBN 1-886651-25-6.

28. Gruessner RW, Sutherland DER: Simultaneous kidney and segmental pancreas transplants from living related donors: the first two successful cases. Transplantation 1996, 61:1265–1268.

29. Stegall M,Wachs M, Kam I: Successful pancreas transplantation in adult-onset diabetes mellitus. Diabetes 1997, 46(Suppl 1):64A.

30. American Diabetes Association: Pancreas transplantation for patients with diabetes mellitus. Diabetes Care 1998, 21(Suppl 1):S79.

31. Sutherland DER, Gruessner RWG: Current status of pancreas transplan-tation for the treatment of type 1 diabetes mellitus. Clin Diabetes 1997, 15:152–156.

32. Ramsay RC, Goetz FC, Sutherland DER, et al.: Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:208–214.

33. Navarro X, Sutherland DER, Kennedy WR: Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997, 42:727–736.

34. Navarro X, Kennedy WR, Sutherland DER:Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia 1991, 34(Suppl 1): S108–S112.

35. Fioretto P, Steffes MW, Sutherland DER, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69–75.

36. Bohman SO, Tyden G,Wilczek, et al.: Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. Diabetes 1985, 34:306–308.

37. Bilous RW, Mauer SM, Sutherland DER, et al.: The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med 1989, 321:80–85.

38. Nathan DM Fogel HA, Norman D, et al.: Long-term metabolic and quality of life results with pancreatic/renal transplantation in IDDM. Transplantation 1991, 52:85–91.

39. Milde FK, Hart LK, Zehr PS: Quality of life of pancreatic transplant recipients. Diabetes Care 1992, 15:1459–1463.

40. Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343(4):230–238.

 

 voltar